Rockwell Medical Technologies (RMTI) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Rockwell Medical Reports Second Quarter 2015 Results
August 4, 2015 4:01 PM EDTWIXOM, Mich., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the second quarter of 2015.
Q2 2015 Financial Highlights
Sales were $13.0 million, in line with Q2 2014. Gross profit was $2.1 million, a 2.3% increase over Q2 2014. Gross profit margins increased to 15.9% compared to 15.5% in Q2 2014. R&D expense was $0.9 million compared to $0.8 million in Q1 2015.... More